Skip to main content
Premium Trial:

Request an Annual Quote

Stelios Papadopoulos

Premium
Regulus Therapeutics, the microRNA joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week announced that it has appointed Stelios Papadopoulos to its board of directors.
 
Papadopoulos recently retired from Cowen and Company, where he served as an investment banker focused on pharmaceuticals and biotechnology, according to Regulus. Before then, he was an investment banker at PaineWebber.
 
He also held faculty positions at New York University Medical Center and continues to be an adjunct associate professor of cell biology at that institution. He holds a PhD in biophysics and an MBA in finance from New York University.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.